Integrating Advocacy Into The Cell & Gene Therapy Supply Chain

By Sharon King, Advocacy and Community Engagement Manager, GMP Nucleic Acids Business Unit, Aldevron

The potential to address the underlying cause of genetic and acquired diseases, gene and cell therapies offer new hope to patients. Having a part in fulfilling this hope serves as one of the primary drivers of our work at Aldevron. In fact, driving meaningful change for patients is the spirit with which we build our client partnerships. Integrating advocacy into the manufacturing supply chain acknowledges our shared commitment and the opportunity for enabling benefit on behalf of patient communities.

Aldevron is a leading provider of critical nucleic acids and proteins used to make gene and cell therapies, DNA and RNA vaccines, and gene editing technologies. The development of these biologic materials is complex, and every process must be carried out with precision. We recognize that when teams understand the purpose behind their work, they are consistently motivated to operate at the highest level of quality and efficiency.